Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.
He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.
Stakeholders List 6 Actionable Steps to Ameliorate Global Disparities in Parkinson Disease
July 11th 2022Advocacy and awareness; prevention and risk reduction; diagnosis, treatment, and care; caregiver support; and research were listed as actionable steps that are urgently needed to address global disparities in Parkinson disease.
Certain Factors May Reduce ESS-Induced Smell Improvement in CRSwNP
July 9th 2022Endoscopic sinus surgery was associated with improvement in self-reported olfactory function among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), in which a longer CRSwNP disease course and higher blood eosinophilia were cited as risk factors linked with poor sense of smell recovery.
Method of Tissue Acquisition May Determine Success of Gene Sequencing in Lung Cancer
July 7th 2022Successful comprehensive genomic profiling of tissue samples among patients with lung cancer was more likely to occur when samples were extracted via resections vs fluid cytology, biopsy, or fine-needle aspirations.
Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile
July 6th 2022Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.
Evaluating Value-Based Contracting in Behavioral Health: A Q&A With Vanessa Bobb, MD, PhD, FAPA
July 5th 2022At AHIP 2022, Vanessa Bobb, MD, PhD, FAPA, vice president of Behavioral Health & Medical Integration at CDPHP, moderated a session on real-world study findings showcasing cost and quality benefits of value-based contracting in behavioral health. Bobb discusses findings of the study and how value-based programs can be better leveraged in mental health and substance abuse care.
Dupilumab Demonstrates Safety, Efficacy Across Several Type 2 Inflammatory Diseases
July 2nd 2022Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 inflammation, including eosinophilic esophagitis (EoE), severe asthma, and severe chronic rhinosinusitis with nasal polyps.
Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis
July 2nd 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.
FCS’ Walcker Outlines His Hopes for Successor Model to OCM
July 1st 2022In the second of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses what he’d like value-based care to look like going forward. CMS ended the Oncology Care Model (OCM) yesterday after 6 years and has invited practices to apply for a successor model, the Enhancing Oncology Model.
Achieving Equity Warrants Change in Public Health Policy and Investment, Panel Says
July 1st 2022Panelists of a keynote session at AHIP 2022 discuss how lessons learned from investment and infrastructure in public health during the COVID-19 pandemic can be leveraged to promote equitable care for all Americans and prepare for the next public health emergency.
Dr Elli Papaemmanuil Discusses Molecular Profiling of MDS, Use of Precision Medicine
June 30th 2022Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.
FCS’ Walcker Explains Value-Based Cancer Care
June 30th 2022In the first of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses the future of value-based care for the practice as the Oncology Care Model comes to an end today. This week, CMS announced it will launch a successor model.
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Stakeholders Address How Digital Therapeutics Can Bridge Unmet Needs in Behavioral Health Care
June 27th 2022Two stakeholders involved in investment and development of behavioral care services discuss the potential of digital therapeutics as a cost-effective alternative to address unmet mental health needs during an AHIP 2022 session.
Dr Robert Sidbury on Promoting Therapeutic Adherence in Pediatric Atopic Dermatitis
June 25th 2022Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, speaks on strategies that clinicians can employ to promote adherence of topical and oral medications in pediatric patients with atopic dermatitis.
Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children
June 24th 2022Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
What’s Next in Health Care? Panelists Highlight Data, Partnerships Post-COVID-19
June 24th 2022Panelists of an AHIP 2022 session discussed how future policy, infrastructure, and investment strategies in public health will reinforce the efforts already made during the pandemic, with partnerships and engagement key to optimize innovation.
Biologic Switching Patterns, Discontinuation in Psoriasis Investigated in New Study
June 22nd 2022An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.
Self-administration of Biologics Well Tolerated, Effective for Asthma and CRS With Nasal Polyps
June 22nd 2022The adequate safety and improved symptom burden observed with self-administration of biologic therapies at home for the management of severe asthma and chronic rhinosinusitis with nasal polyps suggests potential in shifting care away from the more costlier in-patient setting.
Alignment Between Manufacturers, Payers Key to Improving Specialty Drug Affordability and Access
June 22nd 2022Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.
Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis
June 16th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
Nasal Polyps in CRS Found to Influence Risk of Past, Current Proton Pump Inhibitor Use
June 16th 2022Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.
Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity
June 16th 2022Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.
Symptom Burden, QOL in CRSwNP Significantly Improved With Novel Fluticasone Delivery System
June 14th 2022Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.